Theranova
#1
Provide Expanded HD, Retain HD Simplicity.3
#2
Membrane design that combines a higher permeability than regular high-flux dialyser with effective selectivity for large proteins.1, 2
#3
Allows limited albumin removal of between 1 and 4 grams per dialysis session, and features an augmented internal filtration.3
#4
Similar retention rates of endotoxins as other dialysis membranes of the same material.4
Enabling HDx, the Next Evolution in Haemodialysis
With HDx therapy, Theranova* provides superior removal of large middle molecules compared with HD and HDF modalities and it does so using regular HD workflow and infrastructure.3
The Theranova* dialyser series features an innovative membrane design that combines a higher permeability than regular high-flux dialysers with effective selectivity for large proteins.1, 2
* Do not use Theranova dialysers in HDF or HF mode
Provide Expanded HD
Superior removal of large middle molecules (25 kDa to <60 kDa) compared with HD and HDF modalities is delivered with Theranova, with limited albumin removal.3 Greater removal possible for large middle molecules. Applicable to all HD patients.
Retain HD Simplicity
HD infrastructure: no need for HDF capable monitors, nor specific water quality and fluid quality assurance measures.5 HDx therapy is enabled simply by the use of Theranova in HD mode.
Clinical Efficiency and Patient-Reported Outcomes
• Pre-dialysis levels of beta 2 microglobulin and kappa and lambda free light chains were reduced after 3 and 6 months with HDx therapy using the Theranova dialyser in a multi-centric observational study of 41 HD patients.6
• Restless Leg Syndrome criteria are reduced approximately 50% after 6 months for prevalent HD patients in a large observational study by Baxter.7
• A smaller before-after study found no difference in patient-reported symptom burden.8
Learn More About the Theranova Dialyser Series
Read more about how the Theranova dialyser series contributes to Baxter’s dialyser portfolio.